-+ 0.00%
-+ 0.00%
-+ 0.00%
Clearmind Medicine Completes Enrollment for Part C of CMND-100 Phase I/IIa Trial
Share
Listen to the news
Clearmind Medicine Completes Enrollment for Part C of CMND-100 Phase I/IIa Trial
  • Clearmind Medicine completed enrollment for Part C of its Phase I/IIa trial of CMND-100, a non-hallucinogenic treatment candidate for alcohol use disorder.
  • The randomized, placebo-controlled multiple-dose study will assess safety, tolerability and how the drug behaves in the body.
  • Earlier Part A data showed encouraging safety and tolerability in healthy volunteers. Part C data are expected to support future development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160737PRIMZONEFULLFEED9878281) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending